title: In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.
abstract: Several allosteric modulators (AMs) of the CB1 receptor have been characterized in vitro, including Org27569, which enhances CB1-specific binding of [H]CP55,940, but behaves as an insurmountable CB1-receptor antagonist in several biochemical assays. Although a growing body of research has investigated the molecular actions of this unusual AM, it is unknown whether these actions translate to the whole animal. The purpose of the present study was to determine whether Org27569 would produce effects in well-established mouse behavioral assays sensitive to CB1 orthosteric agonists and antagonists. Similar to the orthosteric CB1 antagonist/inverse agonist rimonabant, Org27569 reduced food intake; however, this anorectic effect occurred independently of the CB1 receptor. Org27569 did not elicit CB1-mediated effects alone and lacked efficacy in altering antinociceptive, cataleptic, and hypothermic actions of the orthosteric agonists anandamide, CP55,940, and Δ-tetrahydrocannabinol. Moreover, it did not alter the discriminative stimulus effects of anandamide in FAAH-deficient mice or Δ-tetrahydrocannabinol in wild-type mice in the drug discrimination paradigm. These findings question the utility of Org27569 as a 'gold standard' CB1 AM and underscore the need for the development of CB1 AMs with pharmacology that translates from the molecular level to the whole animal.
authors.affiliation: aDepartment of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia bResearch Triangle Institute International, Durham, North Carolina cSchool of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, Scotland, UK dDepartment of Pharmaceutical Sciences and Center for Drug Discovery, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts, USA eDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Gamage
authors.forename: Bogna M
authors.initials: BM
authors.lastname: Ignatowska-Jankowska
authors.forename: Jenny L
authors.initials: JL
authors.lastname: Wiley
authors.forename: Mostafa
authors.initials: M
authors.lastname: Abdelrahman
authors.forename: Laurent
authors.initials: L
authors.lastname: Trembleau
authors.forename: Iain R
authors.initials: IR
authors.lastname: Greig
authors.forename: Ganesh A
authors.initials: GA
authors.lastname: Thakur
authors.forename: Ritesh
authors.initials: R
authors.lastname: Tichkule
authors.forename: Justin
authors.initials: J
authors.lastname: Poklis
authors.forename: Ruth A
authors.initials: RA
authors.lastname: Ross
authors.forename: Roger G
authors.initials: RG
authors.lastname: Pertwee
authors.forename: Aron H
authors.initials: AH
authors.lastname: Lichtman
mesh_terms: D000494:Allosteric Regulation; D000581:Amidohydrolases / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D063386:Cannabinoid Receptor Agonists / Q000494:pharmacology; D063387:Cannabinoid Receptor Antagonists / Q000494:pharmacology; D063385:Cannabinoid Receptor Modulators / Q000493:pharmacokinetics / Q000494:pharmacology*; D002375:Catalepsy / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D003511:Cyclohexanols / Q000494:pharmacology; D013759:Dronabinol / Q000494:pharmacology; D004341:Drug Evaluation; D004435:Eating / Q000187:drug effects / Q000502:physiology; D063388:Endocannabinoids / Q000494:pharmacology; D005260:Female; D007035:Hypothermia / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D007211:Indoles / Q000493:pharmacokinetics / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D018345:Mice, Knockout; D059225:Nociception / Q000187:drug effects / Q000502:physiology; D010880:Piperidines / Q000493:pharmacokinetics / Q000494:pharmacology*; D053284:Polyunsaturated Alkamides / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D000077285:Rimonabant; D000099252:Fatty Acid Amide Hydrolases
chemical_list: D000581:Amidohydrolases; D001095:Arachidonic Acids; D063386:Cannabinoid Receptor Agonists; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators; D003511:Cyclohexanols; D013759:Dronabinol; D063388:Endocannabinoids; D007211:Indoles; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant; D000099252:Fatty Acid Amide Hydrolases; C572504:5-chloro-3-ethyl-1H-indole-2-carboxylic acid (2-(4-piperidin-1-yl-phenyl)ethyl)amide; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; C078814:anandamide